Transjugular intrahepatic portosystemic shunts vs Conventional treatment
Serious adverse events · adults with hepatorenal syndrome
It is very uncertain whether transjugular intrahepatic portosystemic shunts changes serious adverse events compared with conventional treatment (very low certainty).
1 finding from 1 review
- Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome 2024 · Cochrane Headline outcomes onlyRR 1.6 [0.1, 24.59]2 studies · 130 participantsVery low